Case study of preclinical studies for NASH
Among our lineup is the STAM™ model, which is our proprietary model that shows a 100% progression rate from NASH-HCC. This model also boasts a high clinical correlation and has been featured in over 70 papers and more than 80 presentation. What is more, over 10 of our clients that have used this model have successfully gone on to clinical trial.
To give you an example of clients who have achieved positive results in the STAM™ model, please see the two case studies below:
In both of these examples, we only provided them with the preclinical results, but as you can see they were able to successfully move on to Phase 2 and Phase 3 of clinical trial.
I have talked a lot about liver indications in the email, but I would also like to mention that we have many different inflammation and fibrosis models for different organs, such as the lung and kidney. If you would like to learn more about our models, please contact us.